The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion
- PMID: 21336614
- PMCID: PMC11831574
- DOI: 10.1007/s10880-011-9227-6
The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion
Abstract
The standard of care treatment for chronic hepatitis C viral infection (HCV) is a combination of pegylated interferon alfa and ribavirin for 24-48 weeks according to the virus genotype. This therapy is known to have multiple neuropsychiatric side effects. A major concern when evaluating a patient for HCV treatment with a known history of a psychiatric disorder is the risk that the patient's psychiatric disorder will flare or become unmanageable. The possibility of precipitating depression, confusion, mania, psychosis, hallucinations, or suicidal ideation or attempt is frequently an obstacle to treatment. We present the case of a 50 year-old man with HCV and an extensive psychiatric history involving alcoholism, depression, and suicidality who participated in a psychoeducation group to help prepare him for treatment with pegylated interferon alfa/ribavirin therapy. Though the patient derived much benefit from the psychoeducation group, by the time of evaluation for HCV treatment two months after the group ended he had relapsed back into a depressive episode with suicidal thoughts. His acute psychiatric status made him unacceptable for pegylated interferon alfa/ribavirin therapy. Psychoeducation groups show promise for helping patients with chronic medical illness to be ready for and endure intensive medical treatment that has substantial psychiatric side effects. The challenge is to help patients overcome barriers to treatment, particularly psychosocial problems, because available treatments are increasingly effective.
Similar articles
-
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.Curr Drug Abuse Rev. 2008 Jun;1(2):177-87. doi: 10.2174/1874473710801020177. Curr Drug Abuse Rev. 2008. PMID: 19630716 Review.
-
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.Hepatology. 2007 Oct;46(4):991-8. doi: 10.1002/hep.21791. Hepatology. 2007. PMID: 17668880 Clinical Trial.
-
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.Hepatology. 2003 Feb;37(2):443-51. doi: 10.1053/jhep.2003.50031. Hepatology. 2003. PMID: 12540795
-
Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098. World J Gastroenterol. 2013. PMID: 23467199 Free PMC article.
-
Combination Interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications.Gastroenterol Nurs. 2000 Mar-Apr;23(2):55-62. doi: 10.1097/00001610-200003000-00002. Gastroenterol Nurs. 2000. PMID: 11111599 Review.
Cited by
-
The psychoimmunology of lyme/tick-borne diseases and its association with neuropsychiatric symptoms.Open Neurol J. 2012;6:88-93. doi: 10.2174/1874205X01206010088. Epub 2012 Oct 5. Open Neurol J. 2012. PMID: 23091569 Free PMC article.
-
Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review.Int J Equity Health. 2013 Nov 18;12:92. doi: 10.1186/1475-9276-12-92. Int J Equity Health. 2013. PMID: 24245959 Free PMC article.
-
Psychosocial and Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing.Front Psychol. 2019 Jan 9;9:2666. doi: 10.3389/fpsyg.2018.02666. eCollection 2018. Front Psychol. 2019. PMID: 30687151 Free PMC article. Review.
-
Quality of life and mental health comparisons among liver transplant recipients and cirrhotic patients with different self-perceptions of health.J Clin Psychol Med Settings. 2013 Mar;20(1):97-106. doi: 10.1007/s10880-012-9309-0. J Clin Psychol Med Settings. 2013. PMID: 22622855
References
-
- Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, & Maes M (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders, 72, 237–241. - PubMed
-
- Brau N (2002). Pegylated Interferons and Advances in Therapy for Chronic Hepatitis C. Medscape. http://www.medscape.com/viewproqram/2035pnt. Accessed 11/1/02.
-
- Broers B, Helbling B, Franc A, Schmid P, Chuard C, Hadengue A, et al. (2005). Barriers to interferon—A therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology, 42, 323–328. - PubMed
-
- Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, & Pol S (2006). Treatment of hepatitis C virus and human immunodeficiency virus coinfection: From large trials to real life. Journal of Viral Hepatitis, 13, 678–682. - PubMed
-
- Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, et al.. (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 97, 149–155. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical